News Image

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

Provided By GlobeNewswire

Last update: Oct 12, 2024

-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing-

Read more at globenewswire.com

BENITEC BIOPHARMA INC

NASDAQ:BNTC (7/29/2025, 2:50:54 PM)

11.16

+0.14 (+1.27%)



Find more stocks in the Stock Screener

Follow ChartMill for more